The non-radioisotopic modification of murine local lymph node assay (LLNA) by using 5-bromo-2'-deoxyuridine (BrdU) was conducted to investigate the strain-related difference of the responsiveness of mice to p-benzoquinone (PBQ) with BALB/cAnN, CBA/ JN and CD-1 mouse strains. Strain and dose related differences were analyzed by two-way analysis of variance (two-way ANOVA). CBA/JN was considered to be the highest responsive strain to PBQ, and interaction was detected between CD-1 and each of the other inbred strains. These results support the recommendation in the OECD test guideline 429 and the skin sensitization test guideline of US-EPA with regard to the selection of mouse strain for LLNA.
Contact dermatitis caused by chemicals is a serious health problem, and a prediction of the skin sensitizing potential of chemicals is necessary to secure safe handling of chemicals. The guinea pig maximization test and the Buehler test have been widely used for predicting the skin sensitizing potentials of chemicals for regulatory purposes for a long time [1, 6] . Recently the murine local lymph node assay (LLNA) has been recognized as a new stand-alone sensitization test which can be used for regulatory purposes [3] [4] [5] , and it is based upon consideration of the induced proliferative responses in lymph nodes draining the site of topical exposure to the test chemical. In the standard LLNA, cell proliferation is measured using the incorporation of radiolabeled thymidine or uridine into draining lymph node cells, and this requires specific facilities and handling conditions. We previously developed a non-radioisotopic alternative method for the LLNA which uses 5-bromo-2'-deoxyuridine (BrdU) incorporation in place of radioisotopes [9, 10] . The responsiveness of mouse strains against antigen is known to vary with their H-2 haplotypes. We report here the difference of responsiveness of three mouse strains in the modified murine local lymph node assay against p-benzoquinone, a known potent contact allergen to human.
p-Bebzoquinone ( BZQ, Lot No. 012D2294, Kanto Chemical Co., Tokyo, Japan) was dissolved in acetone:olive oil (AOO; 4:1). 5-Bromo-2'-deoxyuridine (BrdU, Nacalai Tesque, Kyoto, Japan) was dissolved in physiological saline at a concentration of 10 mg/ml. Female CBA/JN, BALB/cAnN and CD-1 mice were obtained from Charles River Japan Ltd. (Kanagawa, Japan). Mice were housed in animal rooms maintained at a temperature of 23 ± 2°C and relative humidity of 55 ± 15%. The rooms were ventilated at a frequency of 10 to 15 cycles/h, and lighted artificially for 12 h daily.
Mice were randomly allocated to 4 groups (4 mice/ group) per each strain of mouse. A 25 µl volume of PBQ in AOO was applied to the dorsum of both ears of the mice daily for three consecutive days. A single intraperitoneal injection (5 mg/mouse/injection) of BrdU was made on day 4. On day 5, auricular lymph nodes were removed, weighed, and stored at -20°C until analysis by an ELISA to measure BrdU incorporation.
BrdU incorporation into the lymph node cells was determined using a commercial cell proliferation assay kit (Boehringer Mannheim Corp., Indianapolis, IN, USA, Cat. No. 1647229). Lymph nodes were crushed, and after passage through a #70 nylon mesh, the cells were suspended in 15 ml of physiological saline. The cell suspension (100 µl) was added to the wells of a flat-bottom microplate (Coster 3595, Corning Inc., NY, USA) in quadruplicate. After centrifugation (3000 × g, 10 min), the supernatants were removed, 200 µl of FixDenat solution was added to each well, and then the plate was allowed to stand for 30 min at room temperature. After removing the Fix-Denat solution, diluted anti-BrdU antibody solution (100 µl, Boehringer Mannheim Corp.) was added to each well, and after rinsing 3 times with washing buffer (phosphate-buffered saline), 100 µl of substrate solution containing tetramethylbenzidine (TMB) was added and allowed to react for 15 min at room temperature. Absorbance at 370 nm was determined as the BrdU labeling index with a microplate reader (SpectraMAX™, Molecular Devices Inc., Sunnyvale, CA, USA) at a reference wavelength of 492 nm. Means and standard errors for the labeling indices were calculated for each treatment group, and the stimulation index (SI) was calculated by dividing the labeling indices in each test group by that in the concurrent vehicle control group. Then, twoway analysis of variance (Two-way ANOVA) was performed with regard to dose and strain as factors.
Dose responses against PBQ for each mouse strain are shown in Fig. 1 . The SI values for 0.25%, 0.5% and 1% PBQ were 3.4, 5.8 and 6.9 in CBA/JN, 2.1, 3.2, and 3.8 in BALB/cAnN, and 2.1, 2.2 and 2.8 in CD-1, respectively. The SI values increased in a dose dependent manner in all mouse strains. Positive responses (SI>3) were noted ≥0.25% in CBA/JN, ≥0.5% in BALB/cAnN and >1.0% in CD-1. As the results of two-way ANOVA, CBA/JN showed the highest responsiveness to PBQ, and interaction was noted between CD-1 and each of the other inbred strains (Table 1) . Consequently, CBA/JN was considered to be the highest responder strain to PBQ, and CD-1 is not a preferable strain for LLNA. In the OECD and US-EPA guidelines [2, 8] , and the ICCVAM validation report for LLNA [7] , CBA/Ca or CBA/J mouse are recommended for selection of animal species. In this study, the CBA/JN mouse showed the highest responsiveness to PBQ among three mouse strains tested. Our result supports the animal selection described in the test guidelines and the review article mentioned above. *Data are represented as the mean ± standard error.
